Mass versus personalized medicine against COVID-19 in the "system sciences" era

Laura Teodori; Barbara Osimani; Ciro Isidoro; Seeram Ramakrishna

doi:10.1002/cyto.a.24662

Mass versus personalized medicine against COVID-19 in the "system sciences" era

Cytometry A. 2022 Dec;101(12):995-999. doi: 10.1002/cyto.a.24662. Epub 2022 Jun 18.

Authors

Laura Teodori¹, Barbara Osimani², Ciro Isidoro³, Seeram Ramakrishna⁴

Affiliations

¹ Laboratory of Diagnostics and Metrology, ENEA, Rome, Italy.
² Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
³ Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.
⁴ Department of Mechanical Engineering, National University of Singapore, Singapore, Singapore.

PMID: 35716116
DOI: 10.1002/cyto.a.24662

Abstract

The importance of personalized/precision medicine for targeted therapies and improved outcomes both in terms of efficacy and safety in health care is by now grounded. We here discuss the current landscape of personalized medicine approaches against SARS-CoV-2. A schematic of the approach is illustrated in the figure in the text.

Keywords: SARS-CoV-2; multi-omics landscape; patient heterogeneity; precision medicine; virus heterogeneity.

MeSH terms

COVID-19*
Humans
Precision Medicine*
SARS-CoV-2